Graves眼病的治疗策略:一项网络Meta分析
该网络Meta分析纳入33项随机对照试验共1846例活动性中重度Graves眼病患者,比较多种干预的疗效与耐受性。多种治疗方案在疗效上显著优于无治疗,其中眶放疗联合静脉糖皮质激素排名第一,霉酚酸酯次之。由于多数证据质量被评为低或极低,作者认为无法就最佳治疗给出稳健推荐。
要点
- 眶放疗联合静脉糖皮质激素(OR 27.11;95%CI 4.57至160.92)与霉酚酸酯(OR 24.40;95%CI 5.28至112.67)疗效显著优于无治疗且排名居前。
- 替妥木单抗(OR 8.92;95%CI 2.51至31.77)、利妥昔单抗(OR 4.85;95%CI 1.18至19.86)等多种方案疗效也显著优于无治疗。
- 利妥昔单抗研究存在高异质性和显著局部不一致性,作者认为无法就最佳治疗给出稳健推荐。
核心结论
- 由于多数证据根据推荐分级的评估、制定与评价框架被评为低或极低质量,作者认为无法就最佳治疗给出稳健推荐。
- 作者提出需要大型随机对照试验和个体参与者数据Meta分析来确认这些结果并探索潜在调节因素。
研究设计与样本
- 研究于2018年7月6日检索PubMed、Embase和Cochrane对照试验中心注册库,纳入研究Graves眼病治疗的随机对照试验。
- 共纳入33项研究、1846例Graves眼病患者,采用频率学方法进行随机效应网络Meta分析。
- 主要结局为疗效,次要结局为耐受性(因副作用停药)。
主要发现
- 眶放疗联合静脉糖皮质激素(OR 27.11;95%CI 4.57至160.92)、霉酚酸酯(OR 24.40;95%CI 5.28至112.67)、口服糖皮质激素联合环孢素(OR 20.22;95%CI 1.60至255.20)疗效显著优于无治疗。
- 静脉糖皮质激素联合霉酚酸酯(OR 12.08;95%CI 2.96至49.35)、替妥木单抗(OR 8.92;95%CI 2.51至31.77)、眶放疗联合口服糖皮质激素(OR 4.88;95%CI 1.25至19.06)疗效显著优于无治疗。
- 利妥昔单抗(OR 4.85;95%CI 1.18至19.86)、生长抑素类似物(OR 4.23;95%CI 1.60至11.16)、口服糖皮质激素联合硫唑嘌呤(OR 5.77;95%CI 1.17至28.47)、静脉糖皮质激素(OR 4.96;95%CI 1.96至12.55)疗效显著优于无治疗。
- 眶放疗联合静脉糖皮质激素排名第一,霉酚酸酯排名第二。
- 利妥昔单抗研究观察到高异质性和显著局部不一致性,敏感性分析结果与主分析相似。
关键数值与推荐
- 眶放疗联合静脉糖皮质激素的OR为27.11(95%CI 4.57至160.92),霉酚酸酯的OR为24.40(95%CI 5.28至112.67),均显著优于无治疗。
- 口服糖皮质激素联合环孢素的OR为20.22(95%CI 1.60至255.20),静脉糖皮质激素联合霉酚酸酯的OR为12.08(95%CI 2.96至49.35)。
- 替妥木单抗的OR为8.92(95%CI 2.51至31.77),眶放疗联合口服糖皮质激素的OR为4.88(95%CI 1.25至19.06)。
- 利妥昔单抗的OR为4.85(95%CI 1.18至19.86),生长抑素类似物的OR为4.23(95%CI 1.60至11.16)。
- 口服糖皮质激素联合硫唑嘌呤的OR为5.77(95%CI 1.17至28.47),静脉糖皮质激素的OR为4.96(95%CI 1.96至12.55)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 大多数证据根据推荐分级的评估、制定与评价框架被评为低或极低质量。
- 利妥昔单抗研究观察到高异质性和显著局部不一致性。
- 作者提出需要大型随机对照试验和个体参与者数据Meta分析来确认这些结果并探索潜在调节因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Various treatments have been investigated for Graves' ophthalmopathy (GO). We aimed to provide an overall profile of the efficacy and tolerability of various interventions for active and moderate to severe GO. METHODS: PubMed, Embase and the Cochrane Central Register of Controlled Trials were searched on 6 July 2018. Randomised controlled trials (RCT) investigating GO treatments were included. Two researchers independently extracted data according to a predefined form. A random effects network meta-analysis was performed using a frequentist approach. The primary outcome was efficacy, and the secondary outcome was tolerability (side effect discontinuation). RESULTS: Thirty-three studies with 1846 patients with GO were included. Orbital radiotherapy (ORT) plus intravenous glucocorticoids (IVGC) (OR 27.11; 95% CI 4.57 to 160.92), mycophenolate mofetil (MMF) (24.40, 95% CI 5.28 to 112.67), oral glucocorticoids (OGC) plus ciclosporin (20.22, 95% CI 1.60 to 255.20), IVGC plus MMF (12.08, 95% CI 2.96 to 49.35), teprotumumab (8.92, 95% CI 2.51 to 31.77), ORT plus OGC (4.88, 95% CI 1.25 to 19.06), rituximab (RTX) (4.85, 95% CI 1.18 to 19.86), somatostatin analogues (4.23, 95% CI 1.60 to 11.16), OGC plus azathioprine (AzA) (5.77, 95% CI 1.17 to 28.47) and IVGC (4.96, 95% CI 1.96 to 12.55) showed significantly better improvement than no treatment. ORT plus IVGC ranked first, followed by MMF. High heterogeneity and significant local inconsistency were observed in the RTX studies. The results of the sensitivity analyses were similar to those of the main analysis. CONCLUSION: A robust recommendation regarding the best treatment cannot be made, because most evidence was rated as low or very low quality according to the Grading of Recommendations, Assessment, Development and Evaluations framework. Large RCTs and individual participant data meta-analyses are necessary to confirm these results and explore potential moderators. PROPERO TRIAL REGISTRATION NUMBER: CRD42018103029.
引用
- Zhou X, Zhou D, Wang J, et al. Treatment strategies for Graves' ophthalmopathy: a network meta-analysis. Br J Ophthalmol. 2019. PMID: 31272958. doi:10.1136/bjophthalmol-2018-313697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。